This is the classic website, which will be retired eventually. Please visit the modernized instead.
Working… Menu

French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management Study (FRENCH CORONA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT04340466
Recruitment Status : Completed
First Posted : April 9, 2020
Last Update Posted : December 19, 2020
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nīmes

Brief Summary:

Since December 2019, a new agent, the SARS-Cov-2 coronavirus has been rapidly spreading from China to other countries causing an international outbreak of respiratory illnesses named COVID-19. In France, the first cases have been reported at the end of January with more than 60000 cases reported since then. A significant proportion (20-30%) of hospitalized COVID-19 patients will be admitted to intensive care unit. However, few data are available for this special population in France.

We conduct a large observational cohort of ICU suspected or proven COVID-19 patients that will enable to describe the initial management of COVID 19 patients admitted to ICU and to identify factors correlated to clinical outcome.

Condition or disease Intervention/treatment
Pneumonia, Viral Critically Ill Corona Virus Infection Other: No intervention

Layout table for study information
Study Type : Observational [Patient Registry]
Actual Enrollment : 1003 participants
Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration: 28 Days
Official Title: French Multicentre Observational Study on SARS-Cov-2 Infections (COVID-19) ICU Management: the FRENCH CORONA Study
Actual Study Start Date : April 3, 2020
Actual Primary Completion Date : July 3, 2020
Actual Study Completion Date : July 3, 2020

Resource links provided by the National Library of Medicine

Group/Cohort Intervention/treatment
Suspected or proven COVID-19 critically ill patients Other: No intervention
No intervention

Control Other: No intervention
No intervention

Primary Outcome Measures :
  1. Mortality at day 28 [ Time Frame: day 28 ]
    Mortality at day 28

Secondary Outcome Measures :
  1. severe complications [ Time Frame: up to day 28 ]
    severe complications (pulmonary embolism, acute kidney injury, myocarditis, cardiac arrest, liver failure, ventilator associated pneumonia) Yes / No

  2. Imaging [ Time Frame: day 1 ]
    Delay in imaging in hours

  3. Delay in Microbiological diagnosis [ Time Frame: day 1 ]
    delay in microbiological diagnosis in hours

  4. Antiviral therapy [ Time Frame: up to day 28 ]
    Antiviral therapy Yes / no

  5. Antibiotic therapy [ Time Frame: day 28 ]
    Antibiotic therapy Yes / No

  6. Covid-19 treatments [ Time Frame: up to day 28 ]
    Covid-19 treatments Yes / No

  7. Patients receiving renal replacement therapy [ Time Frame: up to day 28 ]

  8. Patients receiving mechanical ventilation [ Time Frame: up to day 28 ]

  9. Vital status [ Time Frame: day 28 ]
    Patient alive at day 28 : yes / No

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The target population of the study is all patients with suspected or proven SARS-Cov-2 infection (COVID-19)

Inclusion Criteria:

  • Patients admitted to ICU for suspected or proven SARS-Cov-2 infection, defined by positive SARS-Cov-2 PCR or CT scan images
  • Patient > or= 18 years

Exclusion Criteria:

  • Patient study refusal
  • Patient already enrolled in the present study
  • Patient with respiratory illness with negative COVID-19 CT scan images and negative COVID_19 PCR

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04340466

Layout table for location information
CHU Nimes
Nîmes, France, 30029
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nīmes
Layout table for investigator information
Principal Investigator: CLAIRE ROGER Centre Hospitalier Universitaire de Nīmes
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Nīmes Identifier: NCT04340466    
Other Study ID Numbers: 2020-A00797-32
First Posted: April 9, 2020    Key Record Dates
Last Update Posted: December 19, 2020
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Centre Hospitalier Universitaire de Nīmes:
Intensive Care Unit
Additional relevant MeSH terms:
Layout table for MeSH terms
Communicable Diseases
Coronavirus Infections
Pneumonia, Viral
Critical Illness
Disease Attributes
Pathologic Processes
Respiratory Tract Infections
Virus Diseases
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases